Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.41%
0%
-5.41%
6 Months
-18.6%
0%
-18.6%
1 Year
-33.96%
0%
-33.96%
2 Years
-75.18%
0%
-75.18%
3 Years
-88.89%
0%
-88.89%
4 Years
-95.3%
0%
-95.3%
5 Years
-96.53%
0%
-96.53%
Hybrigenics SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.90%
EBIT Growth (5y)
13.05%
EBIT to Interest (avg)
-3.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.70
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.40
EV to EBIT
-6.50
EV to EBITDA
-6.50
EV to Capital Employed
2.60
EV to Sales
9.10
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-40.00%
ROE (Latest)
-110.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.60
-0.10
-500.00%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.60
-0.10
-500.00%
Operating Profit Margin (Excl OI)
-377,426.20%
0.00%
-37,742.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is 0.00% vs -100.00% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is -500.00% vs 98.67% in Dec 2021
About Hybrigenics SA 
Hybrigenics SA
Pharmaceuticals & Biotechnology
Hybrigenics SA is France-based Company engaged in the biotechnological sector. It specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The Company is specialized in the research and development (R&D) of drugs to fight cancer. It is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. It operates through Hybrigenics Corporation and Imaxio.
Company Coordinates 
Company Details
3-5 impasse Reille , PARIS None : 75014
Registrar Details






